Visweshwar Nathan, Rico Juan Felipe, Killeen Robert, Manoharan Arumugam
Department of Hematology, University of South Florida, Tampa, FL, USA.
Department of Pediatrics, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.
J Hematol. 2023 Aug;12(4):145-160. doi: 10.14740/jh1112. Epub 2023 Aug 31.
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous hematological disorder with malignant potential controlled by immunological characteristics of the tumor microenvironment. Rapid breakthrough in the molecular pathways has made immunological approaches the main anchor in the management of DLBCL, with or without chemotherapeutic agents. Rituximab was the first monoclonal antibody approved for the treatment of DLBCL. Following rituximab that transformed the therapeutic landscape, other novel immunological agents including chimeric antigen T-cell therapy have reshaped the management of relapsed/refractory DLBCL. However, resistance and refractory state remain a challenge in the management of DLBCL. For this literature review, we screened articles from Medline, Embase, Cochrane databases and the European/North American guidelines from March 2010 through October 2022 for DLBCL. Here we discuss immunological agents that will significantly affect future treatment of this aggressive type of lymphoma.
弥漫性大B细胞淋巴瘤（DLBCL）是一种异质性血液系统疾病，其恶性潜能受肿瘤微环境免疫特性的控制。分子途径的迅速突破使免疫治疗方法成为DLBCL治疗的主要支柱，无论是否联合化疗药物。利妥昔单抗是首个被批准用于治疗DLBCL的单克隆抗体。继利妥昔单抗改变了治疗格局之后，其他新型免疫治疗药物，包括嵌合抗原T细胞疗法，重塑了复发/难治性DLBCL的治疗方式。然而，耐药和难治状态仍然是DLBCL治疗中的一个挑战。在本次文献综述中，我们检索了2010年3月至2022年10月期间来自Medline、Embase、Cochrane数据库以及欧洲/北美指南中关于DLBCL的文章。在此，我们讨论将显著影响这种侵袭性淋巴瘤未来治疗的免疫治疗药物。
